The first phase of testing of the coronavirus vaccine candidate in the human body has started at the All India Institute of Medical Sciences (AIIMS) in Delhi. It was applied to the body of a thirty-year-old man on Friday. Indian media Outlook India reported this.
Hyderabad-based India Biotech Corona has developed this vaccine candidate. Its name is Kovaxin. The country’s ICMR and National Institute of Virology (NIV) are included. The Department of Drug Control of India (DCGI) recently allowed human trials of kovaxine.
AIIMS Professor of Community Medicine. Sanjay Roy said that more than three and a half thousand volunteers have already registered to participate in the Kovaskin trial. At least 22 of them are being verified. He said that a Delhi resident, who was tested for two days, became the first volunteer. His health and age were normal and he had no prior morbid condition.
Sanjay Roy said that he was given the first dose at 1.30 pm on Friday afternoon. No immediate side effects were observed. He was kept under observation for two hours. The situation will be reviewed in the next seven days. The first dose will be applied to a few more people on Saturday.
Earlier, the first phase of human trials of ‘Kovasiyan’ started in Roht, Haryana. On July 17, Haryana Health Minister Anil Bij said on Twitter, “Human testing of the corona vaccine conducted by Bharat Biotech has started at PGI from Friday.” The vaccine was given to three volunteers. All three are doing well after the vaccination. ‘